TCR2 Tx Completes Gavo-Cel’s Ph1 Trial; Dosing Started in Gavo-cel’s Pivotal Ph2 Study; Gilead’s KITE-222 Receives Orphan Drug Designation
On Wednesday, September 28, 2022, TCR2 Tx held an investor event highlighting positive topline results from gavo-cel’s (TC-210; autologous mesothelin TRuC-T) Ph1 portion of the Ph1/2 trial (press release / presentation). On Tuesday, September 27, Gilead’s (Kite) KITE-222 (autologous CLL-1 CAR-T) was granted Orphan Drug Designation (ODD) by the FDA (FDA Designation). Below, Celltelligence provides insights on gavo-cel’s positive clinical results and future pivotal development as well as discusses KITE-222’s ODD in AML.